



## **Atlantic Research Group is Awarded Pivotal Phase III IVIG Study**

Staunton, VA January 31, 2011 –

Atlantic Research Group (ARG) announces it has been awarded a multi-year full service contract for The Green Cross Corporation's (South Korea) phase III clinical development of IVIG SN™ (Immune Globulin Intravenous (human) in subjects with Primary Immundeficiency.

This is a multi-center, open-label, multi-year program in the United States and Canada. This is also the Green Cross Corporation's first in-human trial in the United States and will be the initial pivotal program for their organization. This will be the second pivotal plasma derived compound that ARG has managed, the first being Lev Pharmaceutical's Cinryze™, which was awarded BLA approval in late 2008.

ARG will implement TrialVista™, its Clinical Trial Management System (CTMS), to assist in the rapid start up and enrollment of the clinical trial.

Paul Bishop, Managing Partner at Atlantic Research Group said "Our study team has the advantage of TrialVista's™ rapid start-up tools and coupled with our enhanced feasibility modules, will be able to identify investigative sites with potential patients much faster than traditional methods. We are pleased to assist The Green Cross Corporation as they begin enrolling on this pivotal trial."

### **About Atlantic Research Group, Inc. (ARG)**

Atlantic Research Group provides the highest quality clinical monitoring, project management and other clinical support services to biotechnology and pharmaceutical companies. ARG also provides *TrialVista*™, a web-based clinical trial management system, which can be easily customized, to meet individual study needs and reduce start-up costs.

For more information about Atlantic Research Group and *TrialVista*™ please contact Atlantic Research Group directly at 540-213-0150, or visit Atlantic Research Group's website at [www.atlanticresearchgroup.com](http://www.atlanticresearchgroup.com)

###